Efficacy and Safety Analysis of Polyene Phosphatidylcholine and Entecavir in Hepatitis B Cirrhosis
Objective To investigate the effect of polyene phosphatidylcholine and entecavir in hepatitis B cirrhosis(HBC).Methods 65 HBC patients admitted to Ganzhou Fifth People's Hospital from January 2022 to January 2023 were selected,were divided into two groups according to the random number table,the control group(33 cases)and the observation group(32 cases).Both groups received routine treatment,with the control group receiving entecavir and the observation group receiving entecavir+polyene phosphatidylcholine,all for one month continuous treatment.The clinical efficacy,liver function indicators[albumin(ALB),alanine aminotransferase(ALT),total bilirubin(TBIL)],liver fibrosis indicators[laminin(LN),hyaluronidase(HA),procollagen positive peptide(PⅢP),type IV collagen(IV-C)],hepatitis B virus DNA quantification,liver injury degree and application safety were compared between the two groups.Results The total clinical effective rate of the observation group(96.88%)was higher than that of the control group(75.76%)(P<0.05).After treatment,the ALB level in the observation group was higher than in the control group,the levels of ALT,TBIL,LN,HA,PⅢP,IV-C,the quantitative level of hepatitis B virus DNA and the score of liver injury degree in the observation group were lower than those in the control group.There was no statistically significant difference in the incidence of adverse reactions between the two groups(P<0.05).Conclusion The combination of polyene phosphatidylcholine and entecavir in HBC is effective,which can effectively improve the liver function index and liver fibrosis index,reduce the quantitative level of hepatitis B virus DNA,reduce the degree of liver injury,and have good application safety.
Hepatitis B cirrhosisPolyene phosphatidylcholineEntecavirClinical efficacySafety analysisLiver function
NETL
NSTL
万方数据
